Observational studyScientific reports2026
Clinical impact of proteinuria and blood pressure variability on long-term outcomes after percutaneous coronary intervention.
Observational study in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteinuria and blood pressure variability (BPV) are associated with adverse cardiovascular outcomes in coronary artery disease (CAD). However, their combined prognostic impact after percutaneous coronary intervention (PCI) is unknown. To investigate the association of proteinuria and BPV with long-term outcomes after PCI, we analyzed 2,539 patients from an observational PCI registry. Proteinuria was defined as ≥ 1 + on dipstick urinalysis at index hospitalization. BPV was calculated as the standard deviation of systolic blood pressure at follow-up visits and dichotomized at the median. The patients were categorized into four groups based on proteinuria and BPV. The primary endpoint was net adverse clinical events (NACE; all-cause death, nonfatal myocardial infarction, nonfatal stroke, any revascularization, or major bleeding) over 5 years. During a median 5.64-year follow-up period, NACE occurred in 689 patients (27.1%). Both proteinuria and high BPV were independently associated with higher NACE risk. Concomitant proteinuria and high BPV had the highest risk of NACE (hazard ratio, 1.696; 95% confidence interval, 1.341–2.147 vs. no proteinuria and low BPV). The addition of proteinuria and BPV to conventional risk models significantly improved the risk discrimination and reclassification of NACE. Simple dipstick urinalysis and routine BPV assessment may provide complementary prognostic information in patients undergoing PCI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.